ATE516308T1 - Neue immunogene lipopeptide, die t-helfer- und b- zell-epitope enthalten - Google Patents

Neue immunogene lipopeptide, die t-helfer- und b- zell-epitope enthalten

Info

Publication number: ATE516308T1
Authority: AT; Austria
Prior art keywords: helper; cell epitopes; lysine; internal; new immunogenic
Prior art date: 2002-08-12

Application number

AT03783851T

Other languages

English (en)

Inventor

David Jackson

Weiguang Zeng

Original Assignee

Queensland Inst Med Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-12

Filing date

2003-08-12

Publication date

2011-07-15

2003-08-12 Application filed by Queensland Inst Med Res filed Critical Queensland Inst Med Res

2011-07-15 Application granted granted Critical

2011-07-15 Publication of ATE516308T1 publication Critical patent/ATE516308T1/de

Links

108010028921 Lipopeptides Proteins 0.000 title abstract 2
230000002163 immunogen Effects 0.000 title abstract 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
239000004472 Lysine Substances 0.000 abstract 2
210000003719 b-lymphocyte Anatomy 0.000 abstract 2
239000002253 acid Substances 0.000 abstract 1
210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
125000003473 lipid group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Reproductive Health (AREA)
Biophysics (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Virology (AREA)
Hematology (AREA)
Diabetes (AREA)
Oncology (AREA)
Gynecology & Obstetrics (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT03783851T 2002-08-12 2003-08-12 Neue immunogene lipopeptide, die t-helfer- und b- zell-epitope enthalten ATE516308T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40283802P	2002-08-12	2002-08-12
PCT/AU2003/001018 WO2004014956A1 (en)	2002-08-12	2003-08-12	Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes

Publications (1)

Publication Number	Publication Date
ATE516308T1 true ATE516308T1 (de)	2011-07-15

Family

ID=31715903

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03783851T ATE516308T1 (de)	2002-08-12	2003-08-12	Neue immunogene lipopeptide, die t-helfer- und b- zell-epitope enthalten

Country Status (13)

Country	Link
US (2)	US7569225B2 (de)
EP (2)	EP2301972A1 (de)
JP (2)	JP4619120B2 (de)
KR (1)	KR101240547B1 (de)
CN (3)	CN1688606A (de)
AT (1)	ATE516308T1 (de)
AU (1)	AU2003250586B2 (de)
BR (1)	BR0313154A (de)
CA (1)	CA2494192C (de)
DK (1)	DK1543039T3 (de)
ES (1)	ES2369664T3 (de)
HK (1)	HK1113163A1 (de)
WO (1)	WO2004014956A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7255867B2 (en) *	2002-11-15	2007-08-14	Id Biomedical Corporation Of Quebec	Vaccine
JP2008510736A (ja) *	2004-08-26	2008-04-10	ザ・マクファーレーン・バーネット・インスティテュート・フォー・メディカル・リサーチ・アンド・パブリック・ヘルス・リミテッド	ウイルス感染の免疫療法
CA2579775A1 (en)	2004-09-10	2006-03-16	The Council Of The Queensland Institute Of Medical Research (Qimr)	Truncated lhrh formulations
US8420102B2 (en)	2006-03-07	2013-04-16	Vaxinnate Corporation	Compositions that include hemagglutinin
NZ556004A (en) *	2004-12-21	2010-05-28	Vaxinnate Corp	Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
EP1850832B1 (de) *	2005-02-07	2014-12-31	Lipotek PTY Ltd	Adjuvans-material
KR20080013850A (ko) *	2005-02-08	2008-02-13	더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치	면역원성 분자
EP2407178A2 (de)	2005-04-19	2012-01-18	Eli Lilly and Company	Monovalente und polyvalente synthetische Polysaccharidantigene für immunologischen Eingriff bei Krankheit
WO2008021296A2 (en) *	2006-08-14	2008-02-21	Thymon, L.L.C.	Compositions and methods for the treatment and prophylaxis of alzheimer's disease
US7943140B2 (en)	2006-08-14	2011-05-17	Thymon, Llc	Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
BRPI0604997A (pt)	2006-11-30	2007-05-22	Fundacao Zerbini	vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção
US9289485B2 (en)	2006-11-30	2016-03-22	Luiza Guilherme Guglielmi	Therapeutic application of S. pyogenes C-terminal peptide
AU2008310313C1 (en) *	2007-10-09	2015-02-12	Ena Respiratory Pty Ltd	A method of transfection and compositions therefor
WO2009059328A2 (en) *	2007-11-02	2009-05-07	The Johns Hopkins University	Multi- component l2 vaccine for prevention of human papillomavirus infection
US8466259B2 (en) *	2007-12-07	2013-06-18	National Health Research Institutes	Adjuvants
US20110262473A1 (en) *	2008-07-07	2011-10-27	The University Of Melbourne	Synthetic vaccine component
EP2356132A2 (de)	2008-10-16	2011-08-17	Pfizer Inc.	Torque-teno-virus (ttv)-isolate und zusammensetzungen
US8563690B2 (en) *	2008-11-03	2013-10-22	The Board Of Trustees Of The University Of Illinois	Modulation of platelet aggregation
DK2382232T3 (da) *	2008-12-29	2013-12-16	Lonza Braine Sa	Fremgangsmåde til fremstilling af bivalirudin
WO2010115229A1 (en)	2009-04-09	2010-10-14	The University Of Melbourne	Immunogenic composition and uses thereof
US8287880B2 (en)	2009-06-02	2012-10-16	National Health Research Institutes	Lipidated vaccine against dengue virus infection
CN102482327B (zh) *	2009-06-22	2014-10-29	财团法人卫生研究院	脂质化肿瘤相关抗原及其免疫治疗的组成物及方法
DE102009034779A1 (de)	2009-07-25	2011-02-03	Emc Microcollections Gmbh	Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
US8846388B2 (en)	2009-10-16	2014-09-30	Zoetis Llc	Infectious clones of torque teno virus
EP2338521A1 (de)	2009-12-28	2011-06-29	Helmholtz-Zentrum für Infektionsforschung GmbH	Lipopeptid- und Lipoproteinkonjugate und ihre Verwendung
US20130142827A1 (en) *	2010-06-25	2013-06-06	Philadelphia Health & Education Corporation D/B/A	Induction of immune response
RU2586774C2 (ru) *	2010-08-27	2016-06-10	Пантархей Байосайенс Б.В.	Иммунотерапевтический способ лечения рака простаты
US9676819B2 (en) *	2010-09-22	2017-06-13	Innavac Pty Ltd	Immunostimulatory method
TWI507413B (zh)	2010-11-15	2015-11-11	Nat Health Research Institutes	脂質化多抗原表位疫苗
TW201221642A (en)	2010-11-15	2012-06-01	Nat Health Research Institutes	Method of producing lipidated polypeptides
DE102011018499A1 (de)	2011-04-23	2012-10-25	Emc Microcollections Gmbh	Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
US9328142B2 (en) *	2011-05-25	2016-05-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Lipopeptide inhibitors of RAS oncoproteins
WO2012168818A1 (en)	2011-06-08	2012-12-13	Ah Usa 42 Llc	Infectious clones of torque teno virus
WO2013182661A1 (en) *	2012-06-06	2013-12-12	Bionor Immuno As	Peptides derived from viral proteins for use as immunogens and dosage reactants
US10420832B2 (en) *	2012-11-16	2019-09-24	United Biomedical, Inc.	Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD)
CN109893648A (zh)	2013-06-28	2019-06-18	奥克兰联合服务有限公司	氨基酸缀合物和肽缀合物及缀合方法
WO2015157189A1 (en) *	2014-04-07	2015-10-15	The Regents Of The University Of California	Vaccines and uses thereof
BR112017013574A2 (pt)	2014-12-23	2018-03-06	Verdon Daniel	conjugados de aminoácido e peptídeo e usos dos mesmos
GB201513921D0 (en) *	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
WO2017073797A1 (en) *	2015-10-28	2017-05-04	Ajinomoto Co., Inc.	Immunostimulating agent
SG11201807036QA (en)	2016-02-26	2018-09-27	Auckland Uniservices Ltd	Amino acid and peptide conjugates and conjugation process
WO2017165366A1 (en)	2016-03-21	2017-09-28	South Dakota Board Of Regents	Orf virus-based platform for vaccine delivery
DE102016005550A1 (de)	2016-05-09	2017-11-09	Emc Microcollections Gmbh	Adjuvans zur lnduzierung einer zellulären lmmunantwort
CN111148528A (zh)	2016-12-28	2020-05-12	英福瓦克思公司	流感疫苗
CN107703294B (zh) *	2017-10-12	2019-06-04	华派生物工程集团有限公司	一种用于检测鸡血清中cLHRH抗体效价的ELISA方法
CN109991422A (zh) *	2017-12-29	2019-07-09	复旦大学	基于特异抗血清的棕榈酰化修饰蛋白质的检测方法
WO2020257870A1 (en)	2019-06-26	2020-12-30	Ena Therapeutics Pty Ltd	Novel molecules
CN116348594A (zh)	2020-05-13	2023-06-27	美国卫生和人力服务部	携带一个或多个p基因突变的rsv疫苗
CN114315985A (zh)	2020-09-29	2022-04-12	硕腾服务有限责任公司	减毒猪流行性腹泻病毒
TW202233647A (zh) *	2020-11-17	2022-09-01	挪威商霍夫賽思生物保健有限公司	呼吸治療
CN113009141A (zh) *	2021-02-05	2021-06-22	深圳市国赛生物技术有限公司	化学发光免疫检测试剂盒、用途和检测方法
JP2024507457A (ja) *	2021-02-05	2024-02-20	アムジエン・インコーポレーテツド	ハイブリドーマ生成の増強
CN115216451A (zh)	2021-04-16	2022-10-21	硕腾服务有限责任公司	伪狂犬病病毒疫苗
CN118267462A (zh)	2022-12-29	2024-07-02	硕腾服务有限责任公司	接种猪以抗伪狂犬病病毒的方法
WO2024149888A1 (en) *	2023-01-12	2024-07-18	Isa Pharmaceuticals B.V.	Improved lipopeptide quantification

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196265A (en)	1977-06-15	1980-04-01	The Wistar Institute	Method of producing antibodies
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6024964A (en)	1985-06-24	2000-02-15	Hoechst Aktiengesellschaft	Membrane anchor/active compound conjugate, its preparation and its uses
US5864008A (en)	1988-03-25	1999-01-26	James; Stephen	Peptides derived from foot-and-mouth disease virus, pharmaceutical compositions, and methods for using the peptides
DE4119856A1 (de)	1991-06-17	1992-12-24	Hoechst Ag	N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
GB9202219D0 (en)	1992-02-03	1992-03-18	Connaught Lab	A synthetic heamophilus influenzae conjugate vaccine
US5580563A (en)	1992-05-01	1996-12-03	Tam; James P.	Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
AUPM885194A0 (en)	1994-10-14	1994-11-10	Council Of The Queensland Institute Of Medical Research, The	Synthetic peptides and vaccines comprising same
US5807978A (en)	1995-06-07	1998-09-15	Kokolus; William J.	Immunogenic peptides of prostate specific antigen
US6048538A (en)	1997-10-03	2000-04-11	United Biomedical, Inc.	Peptides derived from the non-structural proteins of foot and mouth disease virus as diagnostic reagents
US6107021A (en)	1998-06-20	2000-08-22	United Biomedical, Inc.	Synthetic peptide vaccines for foot-and-mouth disease
DK1147212T3 (da)	1999-02-05	2010-01-04	Univ Melbourne	T-hjælpecelle-epitoper
WO2001070265A2 (en)	2000-03-24	2001-09-27	Biomira, Inc.	Lipopeptide adjuvants

2003
- 2003-08-12 CN CNA038241498A patent/CN1688606A/zh active Granted
- 2003-08-12 CN CN2007101287174A patent/CN101121754B/zh not_active Expired - Fee Related
- 2003-08-12 DK DK03783851.3T patent/DK1543039T3/da active
- 2003-08-12 CA CA2494192A patent/CA2494192C/en not_active Expired - Fee Related
- 2003-08-12 WO PCT/AU2003/001018 patent/WO2004014956A1/en active Application Filing
- 2003-08-12 AT AT03783851T patent/ATE516308T1/de active
- 2003-08-12 CN CN038241498A patent/CN1688606B/zh not_active Expired - Fee Related
- 2003-08-12 BR BR0313154-8A patent/BR0313154A/pt not_active IP Right Cessation
- 2003-08-12 EP EP10011466A patent/EP2301972A1/de not_active Withdrawn
- 2003-08-12 JP JP2004526517A patent/JP4619120B2/ja not_active Expired - Fee Related
- 2003-08-12 US US10/525,301 patent/US7569225B2/en not_active Expired - Fee Related
- 2003-08-12 KR KR1020057002331A patent/KR101240547B1/ko not_active IP Right Cessation
- 2003-08-12 ES ES03783851T patent/ES2369664T3/es not_active Expired - Lifetime
- 2003-08-12 AU AU2003250586A patent/AU2003250586B2/en not_active Ceased
- 2003-08-12 EP EP03783851A patent/EP1543039B1/de not_active Expired - Lifetime
2008
- 2008-08-12 HK HK08108873.7A patent/HK1113163A1/xx unknown
2009
- 2009-06-19 US US12/488,485 patent/US8367067B2/en not_active Expired - Fee Related
- 2009-12-28 JP JP2009298035A patent/JP5265511B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20100092500A1 (en)	2010-04-15
CA2494192A1 (en)	2004-02-19
EP2301972A1 (de)	2011-03-30
US8367067B2 (en)	2013-02-05
BR0313154A (pt)	2005-08-02
US20070066534A1 (en)	2007-03-22
JP4619120B2 (ja)	2011-01-26
CN1688606A (zh)	2005-10-26
EP1543039B1 (de)	2011-07-13
CA2494192C (en)	2013-01-22
AU2003250586A1 (en)	2004-02-25
EP1543039A1 (de)	2005-06-22
EP1543039A4 (de)	2007-09-19
DK1543039T3 (da)	2011-10-31
ES2369664T3 (es)	2011-12-02
WO2004014956A1 (en)	2004-02-19
US7569225B2 (en)	2009-08-04
CN1688606B (zh)	2013-12-25
JP5265511B2 (ja)	2013-08-14
JP2010155832A (ja)	2010-07-15
CN101121754B (zh)	2012-02-29
KR20050053608A (ko)	2005-06-08
CN101121754A (zh)	2008-02-13
KR101240547B1 (ko)	2013-03-08
HK1113163A1 (en)	2008-09-26
JP2006513140A (ja)	2006-04-20
AU2003250586B2 (en)	2010-09-23

Legal Events

Date

Code

Title

Description

2012-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1543039

Country of ref document: EP

Publication	Publication Date	Title
ATE516308T1 (de)	2011-07-15	Neue immunogene lipopeptide, die t-helfer- und b- zell-epitope enthalten
BR0017028A (pt)	2003-01-07	Lipopepìdeos como agentes antibacterianos
PL366826A1 (en)	2005-02-07	Reducing the immunogenicity of fusion proteins
BR0208183A (pt)	2004-03-02	Peptìdeo modificado por wt1
DE69942225D1 (de)	2010-05-20	Künstliche t-helferzell-epitope als immunstimulatoren für synthetische peptidimmunogene
RS51699B (sr)	2011-10-31	Beta-amiloid-analog-t-ćelijski-epitop vakcina
ATE244015T1 (de)	2003-07-15	Formulierungen fuer faktor ix
BR0114994A (pt)	2003-09-30	Composição de vacina
BR0209434A (pt)	2006-02-07	Peptìdeos antimicrobianos e composições
BR9912176A (pt)	2002-11-05	Epìtopos de célula auxiliar t artificial como estimuladores imunes para imunógenos de peptìdeo sintéticos incluindo peptìdeos de lhrh imunogênicos
IL150223A (en)	2013-09-30	Lipopeptides and pharmaceuticals containing them
AU6160201A (en)	2001-11-26	Human polypeptides causing or leading to the killing of cells including lymphoidtumor cells
CY1109230T1 (el)	2014-07-02	Ισομεραση συζευγμενου λινελαϊκου οξεος και μια διαδικασια για την παρασκευη συζευγμενου λινελαϊκου οξεος
AU8524901A (en)	2002-03-13	Membrane penetrating peptides and uses thereof
ATE430160T1 (de)	2009-05-15	Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
BR0314554A (pt)	2005-08-09	ésteres básicos de álcoois graxos e sua aplicação como agentes anti-inflamatórios ou imunomoduladores
HUP0303977A2 (hu)	2004-03-29	Eljárás tiszta foszfatidok előállítására és alkalmazásuk kozmetikai, gyógyászati és élelmezési célokra
FR2717081B1 (fr)	1996-06-21	Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro.
GB9612214D0 (en)	1996-08-14	Vaccine
DE69912827T2 (de)	2004-10-21	"ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen
ES2134474T3 (es)	1999-10-01	Peptidos utilizados como agentes terapeuticos para el tratamiento de enfermedades autoinmunitarias.
DE50002065D1 (de)	2003-06-12	Haarpflegemittel
DK1420757T3 (da)	2006-07-10	Kosmetiske mikroemulsioner indeholdende ectoin eller derivater
CL2004001579A1 (es)	2005-05-20	Composicion farmaceutica que comprende un analogo de somatostatina y acido tartarico, donde la composicion tiene el ph regulado entre 4 y 4,5 y el compuesto activo es l ciclo[{4-(nh2-c2h4-nh-cp-o)pro}-phg-dtrp-lys-tyr(4-bzl)-phe]; y su uso para prepa
ATE95422T1 (de)	1993-10-15	Ein synthetisches nonapeptid zur verwendung als adjuvant.